About Acme Formulation Private Limited
Data last updated:
Acme Formulation Private Limited is a private limited company based in Himachal Pradesh, India, a subsidiary of Pagac Ariane Pte Ltd. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 21 June 2004 and has been in existence for over 22 years.
The company is registered with the Registrar of Companies (ROC), Himachal Pradesh, under CIN U24230HP2004PTC027223. Its GSTIN is 02AAECA7994C1ZT (Himachal Pradesh). The company holds 4 GST registrations, of which 3 are active.
The company has an authorised share capital of ₹18 Cr and a paid-up capital of ₹10.25 Cr. It is led by directors including Viral Shah (Managing Director) and Vikas Sharma (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Village Chowkiwalatehsil Nalagarh Distt Solan, Himachal Pradesh, India.
As per the financials filed for FY 2025, the company reported a revenue of ₹577 Cr, a decline of 2% compared to the previous year. For the same year it recorded a net profit of ₹71.71 Cr (net margin 12.4%) and EBITDA of ₹123.8 Cr (EBITDA margin 21.5%). Revenue has grown at a compounded annual rate (CAGR) of 2% over three years and 12% over five years.
The company has about 601 employees on its provident fund (EPFO) records. Its group structure includes 4 subsidiaries.
The company is associated with 1 brand: Acme Generics. As per MCA filings, the company has open charges of ₹115.72 Cr and satisfied charges of ₹202.58 Cr on record. Court records list 22 cases involving the company, including 11 filed by the company and 11 filed against it; 5 cases are pending. The company has 10 deals on record (9 secondary share transfers, 1 funding round), with disclosed funding of ₹547.74 Cr; the latest was in October 2021. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 5 smaller; the largest is Sri Krishna Pharmaceuticals Limited with revenue of ₹608.24 Cr. The company has 17 MSME Form 1 returns on record between 2018 and 2024, listing 1,424 overdue payments to 27 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website acmegenerics.in.
Company details
Contact details
Acme Formulation Private Limited's registered office is in Himachal Pradesh. Its website is acmegenerics.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressVillage Chowkiwalatehsil Nalagarh Distt Solan, Himachal Pradesh, India
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Acme Formulation Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Acme Formulation operates one associated brand: Acme Generics. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Solid and liquid formulations are manufactured as a CDMO focus. | acmegenerics.in |
Business activity
The main business activity of Acme Formulation is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Acme Formulation Private Limited, buy the company report.
Financials of Acme Formulation Private Limited
FY 2024 filings availableAcme Formulation Private Limited reported revenue of ₹577 Cr (down 2% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 2% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 12%. EBITDA rose 26% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹123.8 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹71.71 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 21.5% | ||||
| Net Profit Margin | 12.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Acme Formulation Private Limited, buy the company report.
Board of directors of Acme Formulation Private Limited
Acme Formulation has 4 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Viral Shah Also directs: Ambriel Life Sciences LLP, Acme Generics Private Limited, Tekno Touch Private Limited and 3 more | Managing Director | 24 Jan 2007 | 19 Years 9 Months | Current |
| Aswin Vikram Also directs: Nuvama Wealth Management Limited, Pagac Advisors India Private Limited, Alternicq Limited and 4 more | Director | 04 Oct 2021 | 5 Years 0 Months | Current |
| Vikas Sharma Also directs: Acme Generics Private Limited, Ace Testing Solutions Private Limited, Ace Invest Private Limited and 1 more | Whole-Time Director | 29 Jul 2020 | 6 Years 3 Months | Current |
| Nikhil Kumar Srivastava | Director | 04 Oct 2021 | 5 Years 0 Months | Current |
Peer comparison
Acme Formulation Private Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sri Krishna Pharmaceuticals Limited | ₹608.24 Cr (FY 2025) | -13.0% | Telangana, India | |||
| Wanbury Limited | ₹603.01 Cr (FY 2025) | 4.0% | Navi Mumbai, Maharashtra, India | |||
| Malik Lifesciences Private Limited | ₹595.52 Cr (FY 2025) | 11.0% | Delhi, India | |||
| Acme Formulation Private Limitedthis company | ₹577 Cr (FY 2025) | ₹71.71 Cr | 12.4% | -2.0% | 601 | Himachal Pradesh, India |
| Bajaj Healthcare Limited | ₹562.01 Cr (FY 2025) | 17.0% | Thane, Maharashtra, India | |||
| G S Pharmbutor Private Limited | ₹561.56 Cr (FY 2025) | 6.0% | Rudrapur, Uttarakhand, India | |||
| Ind Swift Limited | ₹560.24 Cr (FY 2024) | 33.0% | Chandigarh, India | |||
| Shalina Laboratories Private Limited | ₹551.12 Cr (FY 2023) | -1.0% | Mumbai, Maharashtra, India | |||
| German Remedies Pharmaceuticals Private Limited | ₹546.98 Cr (FY 2025) | 9.0% | Ahmedabad, Gujarat, India |
To see the full peer comparison of Acme Formulation Private Limited, buy the company report.
Auditor
Acme Formulation Private Limited is audited by S. R. Batliboi & Co. LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S. R. Batliboi & Co. LLP | FY 2023 | 301003E/E300005 |
Shareholding
The shareholding of Acme Formulation Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2018 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Acme Formulation Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 06 Aug 2021 | 100484075 | State Bank of India | ₹50.72 Cr | Open | |
| 17 Jan 2020 | 100320703 | Hdfc Bank Limited | ₹30.5 Cr | Open | |
| 17 Jan 2020 | 100320568 | Hdfc Bank Limited | ₹8.5 Cr | Open | |
| 17 Jan 2020 | 100320572 | Hdfc Bank Limited | ₹26 Cr | Open | |
| 23 Nov 2016 | 100063197 | Hdfc Bank Limited | ₹25.5 Cr | Satisfied |
To see the full charge records of Acme Formulation Private Limited, buy the company report.
Total charge records: 18 View all charges
Deals & funding
Acme Formulation Private Limited has 10 deals on record (9 secondary share transfers, 1 funding round), with disclosed funding of ₹547.74 Cr; the latest was in October 2021.
Deals on record (5 of 10)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Oct 2021 | Secondary share transfer | Undisclosed | Seller: JCBL India Private Limited , an individual |
| Mar 2021 | Secondary share transfer | Undisclosed | Buyer: JCBL India Private Limited Seller: an individual |
| Jan 2013 | Secondary share transfer | Undisclosed | Buyer: JCBL India Private Limited Seller: an individual |
| Aug 2005 | Secondary share transfer | Undisclosed | Buyer: JCBL India Private Limited , 2 individuals Seller: 2 individuals |
| Jul 2005 | Secondary share transfer | Undisclosed | Buyer: JCBL India Private Limited , an individual Seller: 2 individuals |
To see the full deal history of Acme Formulation Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Acme Formulation Private Limited has 22 court cases on record: 11 filed by Acme Formulation, 11 filed against it. 5 cases are pending and 17 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 19 | 10 | 4 |
| High courts | 3 | 1 | 1 |
Cases on record (5 of 22)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Chandigarh | Court case (TA CIVIL) | Filed by the company against Ms C.S.J. Infrastructure Pvt. Ltd, | Disposed |
| High Court, HIMACHAL PRADESH | Civil suit | Filed by the company against Medley Pharmaceuticals Ltd(Not Applicable) | Disposed |
| District court, Kushinagar, Uttar Pradesh | Criminal miscellaneous application | Filed against the company by State of Uttar Pradesh | Pending |
| High Court of Gujarat | Appeal | Filed by the company against Dashrathbhai Kalidas Patel,Prop. Ms Acme Pharmaceuticals | Pending |
| District court, Kushinagar, Uttar Pradesh | Criminal miscellaneous application | Filed against the company by State Government of Uttar Pradesh | Pending |
To see the full case history of Acme Formulation Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Acme Formulation Private Limited was last rated by Icra on 31 Jan 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Icra | 31 Jan 2022 |
To see the full credit ratings and regulatory alerts of Acme Formulation Private Limited, buy the company report.
MSME payment delays
Acme Formulation Private Limited has 17 MSME Form 1 returns on record between 2018 and 2024, listing 1,424 overdue payments to 27 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 27)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| B.S. Mehra Sons Pvt Ltd | |||
| Symbio Generrics India Pvt. Ltd | |||
| Ideal Cures Private Limited | |||
| Sunshine Organics Pvt Ltd | |||
| an individual supplier |
To see the full MSME payment records of Acme Formulation Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Acme Formulation has 4 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Acme Generics Private Limited | U24100PB2021PTC056566 | |
| Ace Testing Solutions Private Limited | U74140HP2009PTC031248 | |
| Ace Invest Private Limited | U74900CH2013PTC034318 | |
| Immacule Lifesciences Private Limited | U74900HP2010PTC031676 |
To see the full group structure of Acme Formulation Private Limited, buy the company report.
Employees & EPFO
Acme Formulation Private Limited has a workforce of 601 employees on its EPFO records as of Mar 28, 2024, across 1 active EPFO establishment.
GST
Acme Formulation has 4 GST registrations: 3 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 02AAECA7994C1ZT | Himachal Pradesh | Active | 01 Jul 2017 |
| 04AAECA7994C2ZO | Chandigarh | Active | 21 Jul 2017 |
| 03AAECA7994C1ZR | Punjab | Active | 25 Oct 2021 |
To see the full GST registrations and return filing status of Acme Formulation Private Limited, buy the company report.
Recent activity
Acme Formulation Private Limited has 20 board changes on record since 2004: 12 appointments and 8 cessations. The latest: Annaswamy Vaidheesh ceased to be Director on 01 Apr 2023.
53 earlier events are in the company report.
News
Frequently asked questions
Acme Formulation is an active private limited company based in Himachal Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 21 June 2004 (22+ years old) and is registered under CIN U24230HP2004PTC027223.
Acme Formulation has 4 current directors:
- Viral Shah - Managing Director
- Vikas Sharma - Whole-Time Director
- Aswin Vikram - Director
- Nikhil Kumar Srivastava - Director
The latest financial statements of Acme Formulation on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Acme Formulation is 02AAECA7994C1ZT, registered in Himachal Pradesh. The company has 4 GST registrations in all, of which 3 are active and 1 is cancelled or inactive. Other active GSTINs include 04AAECA7994C2ZO (Chandigarh), 03AAECA7994C1ZR (Punjab).
The CIN (Corporate Identification Number) of Acme Formulation is U24230HP2004PTC027223. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Acme Formulation has 22 court cases on record: 11 filed by the company and 11 filed against it. 5 are pending. Most are in the district courts.
Acme Formulation was incorporated on 21 June 2004, making it 22+ years old. It is registered with the Registrar of Companies, Himachal Pradesh.
Acme Formulation has 10 deals on record (9 secondary share transfers, 1 funding round), with disclosed funding of ₹547.74 Cr; the latest was in October 2021.
The peers of Acme Formulation by revenue are Sri Krishna Pharmaceuticals Limited, Wanbury Limited, Malik Lifesciences Private Limited, Bajaj Healthcare Limited, G S Pharmbutor Private Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Annaswamy Vaidheesh ceased to be Director on 01 Apr 2023. Sundar Raj Ananthakrishnan ceased to be Additional Director on 22 Nov 2022. Sundar Raj Ananthakrishnan was appointed as Additional Director on 20 Jun 2022. Acme Formulation has 20 board changes on record in total.
Acme Formulation has 17 MSME Form 1 returns on record between 2018 and 2024, listing 1,424 overdue payments to 27 micro and small suppliers. The latest return was filed on 29 Apr 2024.
Acme Formulation can be reached through the website acmegenerics.in. Its registered office is in Himachal Pradesh, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
